Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2007

View Archived Issues

Tego and NCI collaborate on development of fullerene formulation

Gilead reports promising phase III results for chronic hepatitis B

CytRx identifies arimoclomol dose for phase IIb trial

Positive phase I findings for topical antibiotic REP-8839

OBE-101 phase II obesity trial completes treatment

Beta-secretase inhibitor CTS-21166 begins initial phase I study

New trials commence for Heplisav

Roche completes acquisition of BioVeris

Ketasyn advances for the treatment of Alzheimer's disease

Enrollment opens for phase IIa study of KP-1461 in HIV

Intradigm selects Agilent for siRNA manufacturing

Positive results for deCODE's drug candidate DG-041 for arterial thrombosis

Molecular Insight initiates phase II pivotal registration trial for Zemiva

UCB and Biogen Idec's initiate phase II study of CDP-323 for MS

Novel SGLT inhibitors reduce postprandrial hyperglycemia in diabetic rats

DPP-IV inhibition with S-40010 enhances pancreatic beta-cell mass and reduces postprandrial glycemia

PSN-119-1: A GPR119 receptor agonist with antidiabetic and antiobesity properties

Positive results with novel selective PPARalpha agonist in diabetic monkeys

Potential targets for the treatment of sleep disorders

Amgen's new TRPV1 antagonist shows analgesic efficacy in rat pain models

Novel agents for HIV infection reported in recent Bristol-Myers Squibb patent

Novel analgesic agents imparted in recent Novartis and Novartis Pharma patents

Priority review granted for Isentress

New therapeutic agents for neurological disorders reported in recent patents

Rotarix filed for U.S. approval

Supplemental NDA filed for Nexavar in hepatocellular carcinoma

Tasigna submitted in Japan

Actos filed for use in combination with insulin in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...